Vaidya Govindarajan Joshua D Burks Evan M Luther John W Thompson Robert M Starke
10.1159/000515168
Cerebrovasc Dis
2021;50(5):493-499.
adjuvant arteriovenous malformation bleeding embolization inoperable medical therapy molecular target of rapamycin rapamycin surgery vascular malformation
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/34198289/
Arteriovenous Malformations / therapy Face / blood supply Immunosuppressive Agents / therapeutic use Intracranial Arteriovenous Malformations / therapy Sirolimus / therapeutic use TOR Serine-Threonine Kinases / antagonists & inhibitors
Arteriovenous Malformations / therapy Face / blood supply Immunosuppressive Agents / therapeutic use Intracranial Arteriovenous Malformations / therapy Sirolimus / therapeutic use TOR Serine-Threonine Kinases / antagonists & inhibitors Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review Adult Arteriovenous Malformations / diagnostic imaging Arteriovenous Malformations / enzymology Arteriovenous Malformations / immunology Combined Modality Therapy Embolization, Therapeutic Female Humans Intracranial Arteriovenous Malformations / diagnostic imaging Intracranial Arteriovenous Malformations / enzymology Intracranial Arteriovenous Malformations / immunology TOR Serine-Threonine Kinases / metabolism Treatment Outcome Young Adult Immunosuppressive Agents MTOR protein, human TOR Serine-Threonine Kinases Sirolimus
PMC8440490
34198289
Medical Adjuvants in the Treatment of Surgically Refractory Arteriovenous Malformations of the Head and Face: Case Report and Review of Literature
2021